Français Japonais Chinois Allemand Néerlandais Espagnol Portugais

    News

    Success story: Amaris Lille set to expand

    Switzerland-based Amaris opened an office in Hauts-de-France in late 2015. Ranked among Europe’s leading independent consulting groups, the company is growing exponentially.

    Lille shortlisted as World Design Capital 2020

    Greater Lille and Sydney are the finalists for the biennial title, awarded by the World Design Organization.

    All news

    Radiotherapy breakthrough: Oscar Lambret Center celebrates world first

    20 Aug 2013 | A region on the move, Health Nutrition

    Lille's Oscar Lambret Center, a standard-setter in cancer treatment, offers increasingly innovative and targeted therapies

    Oscar-Lambret - TomoTherapy - Radiotherapy - hospital - cancer - Lille Region

    In 2012, the Oscar Lambret Center acquired its third TomoTherapy platform—a new TomoHDA™ that harnesses imaging technology to deliver intensity-modulated radiation therapy (IMRT). Oncologists and radiation therapists at the center can now "use 3-dimensional images to administer ultra-targeted radiation treatments," says Dr. Éric Lartigau, Director of Research and Cooperation at the center.

    The primary benefits of this innovative technology are spectacular improvement in patients’ radiation tolerance and integrated radiation scheduling and delivery. "This is the best possible treatment scenario,” says Dr. Lartigau. “We can administer high-dose radiation to the tumor while protecting healthy organs.” And there’s an additional benefit for patients: "treatments are better tolerated¬—each session is shorter, too—and there are fewer side effects, so we can complete full cycles with no interruptions. That's a critical advantage for effective treatment," notes Lartigau.

    The breakthrough was the product of an ongoing partnership launched six years ago between teams at the Oscar Lambret Center and at Accuray, a global leader in radiotherapy and manufacturer of the TomoHDA™. The world’s first treatments with the unit were administered on April 23 this year and have proven completely safe. To date it has improved the lives of 70 patients.

    Source: Unicancer, La Voix du nord

    Back to news